Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth (Status and Outlook) 2025-2031

According to this study, the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size will reach US$ million by 2031.

Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.



Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.

Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.

Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.

United States market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics players cover Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Forecast” looks at past sales and reviews total world Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics sales for 2025 through 2031. With Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:
Stimulants
Non-stimulants

Segmentation by Application:
Pediatric and Adolescents
Adults

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories

Please note: The report will take approximately 2 business days to prepare and deliver. Show more